MedTrace Logo

Extension Study of the Safety and Efficacy of Atiprimod Treatment in Neuroendocrine Carcinoma

NCT00663429 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 10

Last updated 2011-08-31

No results posted yet for this study

Summary

This study is an extension study to the Callisto protocol CP-106. Subjects must have completed all 12 treatment cycles of CP-106 without disease progression as per RECIST criteria,to be eligible to to be enrolled in this study. This study will evaluate the safety and efficacy of atiprimod treatment in patients with low to intermediate grade neuroendocrine carcinoma who have metastatic or unresectable local-regional cancer and who have either symptoms (diarrhea, flushing and/or wheezing) despite standard therapy (octreotide) or progression of neuroendocrine tumor(s).

Conditions

  • Neuroendocrine Carcinoma

Interventions

DRUG

Atiprimod

Oral, 14 days on / 14 days off; 30mg capsules

Sponsors & Collaborators

  • Callisto Pharmaceuticals

    lead INDUSTRY

Principal Investigators

  • Gary S Jacob, PhD · Callisto Pharmaceuticals

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-11-30
Primary Completion
2010-03-31
Completion
2010-03-31

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00663429 on ClinicalTrials.gov